浙江奥翔药业股份有限公司关于完成《公司章程》备案的公告

Group 1 - The company has completed the registration of amendments to its Articles of Association, including the cancellation of the supervisory board, as approved in the recent board and shareholder meetings [1][3] - The adjustments made to the Articles of Association do not have substantive differences from the version approved at the shareholder meeting [1] - The company has disclosed the updated Articles of Association in accordance with the requirements of the Zhejiang Provincial Market Supervision Administration [1] Group 2 - As of December 10, 2025, the company has repaid a total of RMB 80 million of idle funds raised from the 2020 non-public offering, which were temporarily used to supplement working capital [4][7] - The company had previously used the entire RMB 80 million for temporary working capital and has now fully repaid this amount to the designated account [7] - The company also utilized RMB 150 million from the 2022 non-public offering for temporary working capital, which remains unpaid as of the announcement date [6][7]